| Q49073549 | 31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients |
| Q57750810 | A magnetization transfer study of mild and advanced Parkinson’s disease |
| Q48723423 | A multi-ingredient dietary supplement abolishes large-scale brain cell loss, improves sensory function, and prevents neuronal atrophy in aging mice |
| Q36296613 | A nested phosphorus and proton coil array for brain magnetic resonance imaging and spectroscopy |
| Q30835548 | A review of the use of magnetic resonance imaging in Parkinson's disease |
| Q101410046 | A transition to degeneration triggered by oxidative stress in degenerative disorders |
| Q30435807 | ALS spinal neurons show varied and reduced mtDNA gene copy numbers and increased mtDNA gene deletions |
| Q92404148 | Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging |
| Q28662048 | Animal models and high field imaging and spectroscopy |
| Q64239533 | Benefits of Vitamins in the Treatment of Parkinson's Disease |
| Q35570253 | Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study |
| Q43184352 | Both creatine and its product phosphocreatine reduce oxidative stress and afford neuroprotection in an in vitro Parkinson's model |
| Q28554706 | Chemical Compensation of Mitochondrial Phospholipid Depletion in Yeast and Animal Models of Parkinson's Disease |
| Q33642214 | Clinical protocols for ³¹P MRS of the brain and their use in evaluating optic pathway gliomas in children |
| Q37514441 | Covariation between plasma phosphate and daytime cortisol in early Parkinson's disease |
| Q38152514 | Differences between conventional and nonconventional MRI techniques in Parkinson's disease |
| Q28479192 | Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS |
| Q28389950 | Energy failure: does it contribute to neurodegeneration? |
| Q41141822 | Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. |
| Q37939755 | Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline |
| Q38996403 | Exploring the power of yeast to model aging and age-related neurodegenerative disorders |
| Q39765110 | GPA protects the nigrostriatal dopamine system by enhancing mitochondrial function |
| Q36079846 | Hyper-connectivity of the thalamus during early stages following mild traumatic brain injury |
| Q92441183 | In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson's Disease |
| Q47853442 | In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas |
| Q47901306 | Inhibitory motor dysfunction in parkinson's disease subtypes |
| Q33675964 | Innovative MRI techniques in Parkinson's disease |
| Q35743578 | Intraventricular cerebrospinal fluid temperature analysis using MR diffusion-weighted imaging thermometry in Parkinson's disease patients, multiple system atrophy patients, and healthy subjects |
| Q85125086 | Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+) |
| Q41278610 | Lipid disequilibrium in biological membranes, a possible pathway to neurodegeneration |
| Q36314846 | Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease |
| Q30858994 | Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease? |
| Q43602363 | Metabolic changes in patients with aneurysmal subarachnoid hemorrhage apart from perfusion deficits: neuronal mitochondrial injury? |
| Q26999015 | Metabolic disturbances in diseases with neurological involvement |
| Q48735228 | Metabolic gray matter changes of adolescents with anorexia nervosa in combined MR proton and phosphorus spectroscopy |
| Q26992344 | Metabolomics of human brain aging and age-related neurodegenerative diseases |
| Q36745271 | Mitochondria in neurodegeneration |
| Q39016389 | Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment. |
| Q48018054 | Mitochondrial activity in the frontal cortex area 8 and angular gyrus in Parkinson's disease and Parkinson's disease with dementia |
| Q38811534 | Mitochondrial control of cell bioenergetics in Parkinson's disease. |
| Q28732683 | Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying |
| Q38887346 | Molecular changes in the postmortem parkinsonian brain |
| Q92817653 | NRF2 as a Therapeutic Target in Neurodegenerative Diseases |
| Q48598969 | Native DIGE proteomic analysis of mitochondria from substantia nigra and striatum during neuronal degeneration and its compensation in an animal model of early Parkinson's disease |
| Q83316032 | Neuroimaging in Parkinson's disease |
| Q42108095 | Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease |
| Q26798897 | Oxidative stress and Parkinson's disease |
| Q37834648 | Parkinson's disease--the continuing search for biomarkers |
| Q92465171 | Parkinson's disease: proteinopathy or lipidopathy? |
| Q39655523 | Pathogenic lysosomal depletion in Parkinson's disease |
| Q34281004 | Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease |
| Q38201685 | Preconditioning as a potential strategy for the prevention of Parkinson's disease. |
| Q35698532 | Primary motor cortex in stroke: a functional MRI-guided proton MR spectroscopic study. |
| Q48371760 | Purine metabolism gene deregulation in Parkinson's disease |
| Q30451005 | Stem cell-based models and therapies for neurodegenerative diseases |
| Q35990732 | Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease |
| Q28115295 | Substitution p.A350V in Na⁺/Mg²⁺ exchanger SLC41A1, potentially associated with Parkinson's disease, is a gain-of-function mutation |
| Q42010967 | The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease |
| Q34516419 | The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutations |
| Q64884036 | The effect of succinate on brain NADH/NAD+ redox state and high energy phosphate metabolism in acute traumatic brain injury. |
| Q38105645 | The hallmarks of Parkinson's disease |
| Q31041660 | The role of biomarkers and imaging in Parkinson's disease. |
| Q83834944 | Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease |
| Q48232790 | Translational approaches to restoring mitochondrial function in Parkinson's disease. |
| Q39297719 | Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. |
| Q28394946 | Vulnerability of welders to manganese exposure--a neuroimaging study |